Araclon Biotech is a privately-held biotechnology company, in which the majority shareholder is Grifols, a global healthcare company with world-leading position in plasma-derived technologies and medicines. Araclon is dedicated to the research and development of immunotherapies and diagnostic methods used in the treatment of degenerative diseases, and is currently focused on Alzheimer's disease. At present, Araclon is working on various projects: The first of these focuses on the diagnosis of Alzheimer's disease with detection kits, ABtest, for beta-amyloid 40, 42 and 17 proteins in blood, with a new laboratory service opened recently in Boston, an integrated ABtesting service for the quantification of A in plasma. The second project is centered on development of an effective immunotherapy against Alzheimer's. The third is a project related to the development of a therapy for Parkinson's disease.
| Website | http://www.araclon.com |
| Revenue | $6 million |
| Employees | View employees |
| Founded | 2004 |
| Address | 21 Vía Hispanidad, Zaragoza, Aragon 50009, ES |
| Phone | +34 976 79 65 62 |
| Fax | +34 976 21 78 02 |
| Technologies |
JavaScript
,
PHP
,
Google Analytics
+5 more
(view full list)
|
| Industry | Biotechnology, Business Services General, Biopharma, Business Services, Drug Discovery, Health Care, Science and Engineering, Life Science |
| Competitors | Biogen, Amgen, Lilly India, Roche, AstraZeneca, Pfizer, Novartis, Sanofi, Merck & Co., Inc., Johnson & Johnson +42 more (view full list) |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 541713 Companies |
Looking for a particular Araclon Biotech employee's phone or email?
Araclon Biotech Questions
The Araclon Biotech annual revenue was $6 million in 2026.
Araclon Biotech is based in Zaragoza, Aragon.
The NAICS codes for Araclon Biotech are [54, 54171, 5417, 541, 541713].
The SIC codes for Araclon Biotech are [873, 87].
